Single center experience of mesothelioma patients in southeast region of turkey;Güneydoǧu Anadolu Bölgesinde Mezotelyoma Tanili Olgularda Tek Merkez Deneyimi

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

Volumn 19, Issue 3, 2009, Pages 153-158

  Cil, Timucin ^a   Isikdogan, Abdurrahman ^a   Onat, Serdar ^b   Zincircioglu, Burhanettin ^b   Ulku, Refik ^b   Ozekinci, Selver ^b   Ates, Gungor ^a   Senyigit, Abdurrahman ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

Author keywords

Cancer; Chemotherapy; Mesothelioma

Indexed keywords

CARBOPLATIN; GEMCITABINE; PEMETREXED; ZEOLITE;

ARTICLE; ASBESTOSIS; CANCER PATIENT; CHEMOTHERAPY; CITY; CLINICAL ARTICLE; DEMOGRAPHY; ENDEMIC DISEASE; ENVIRONMENTAL EXPOSURE; HUMAN; MALIGNANT MESOTHELIOMA; PERICARDIAL DISEASE; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; RADIATION; RETROSPECTIVE STUDY; RURAL AREA; SEROSA; TESTIS CANCER; TREATMENT RESPONSE; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

EID: 72949084833     PISSN: 1306133X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging 24: 293-328,1985.
2. Sivirikoz MC, Yildirim H, Tulay MC, et al. Local Pleural Malignant Mesothelioma. Turkiye Klinikleri J Med Sci 27: 800-801, 2007.
3. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 107(suppl): 332-334, 1995.
4. Selcuk ZT, Coplu L, Emri S, et al. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey: Analysis of 135 cases Chest 102: 790-796, 1992.
5. Nishimura SL, Broaddus VC. Asbestos-induced pleural disease. Clin Chest Med 19: 311-329, 1998.
6. Turler A, Monig SP, Raab M. Problems in diagnosis and therapy of malignant pleural mesothelioma. Med Klin 92: 101-105, 1997.
7. Sahin AA, Coplu L, Selcuk ZT, et al. Pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. AJR 161: 533-537, 1993.
8. Yaziicioglu S. Pleural calcification associated with exposure to chrysotile asbestos in Southeast Turkey. Chest 70: 43-47, 1976.
9. Yaziicioglu S, Ilcayto R, Balci K, et al. Pleural calcification, pleural mesotheliomas, and bronchial cancers caused by tremolite dust. Thorax 35: 564-569, 1980.
10. Burdorf A, Jarvholm B, Englund A. Explaining differences in incidence rates pleural rates of mesothelyoma between sweden and Netherlands. Int J Cancer 113: 298-301, 2005.
11. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 45: 379-387, 2007.
12. Bianchi C, Bianchi T. Geography of mesothelioma: An overview. In: CD of Annals of the global Asbestos congress, November 19-21, 2004.
13. Senyigit A, Babayigit C, Gokirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration 67: 610-614, 2000.
14. Schwartz DA. New developments in asbestosinduced pleural disease. Chest 99: 191-8, 1991.
15. Adams VI, Unni KK, Muhm JR, et al. Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases. Cancer 58: 1540-1551, 1986.
16. Brenner J, Sordillo PP, Magill GB. Malignant mesothelioma of the pleura: Review of 123 patients. Cancer 49: 2431-245, 1982.
17. Boutin C, Schlesser M, Frenay C, et al. Malignant pleural mesothelioma. Eur Respir J 12: 972-981, 1998.
18. Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging 24: 293-328, 1985.
19. Santos C, Montesinos J, Castañer E, et al. Primary pericardial mesothelioma. Lung Cancer 60: 291-293, 2008.
20. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis. Lung Cancer 38: 111-121, 2002.
21. Van Meerbeeck J, Debruyne C, van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74: 961-963, 1996.
22. Vorobiof DA, Rapoport BL, Chasen MR, et al. Malignant pleural mesothelioma: A phase II trial with docetaxel. Ann Oncol 13: 412-415, 2002.
23. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 17: 25-30, 1999.
24. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-644, 2003.
25. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889, 2005.